Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Clinical Care/Education/Nutrition

Glucose-Lowering Effects of Sulfasalazine in Type 2 Diabetes

  1. Romana M. Haas, MD1,
  2. Phoebe Li, PHARMD2 and
  3. James W. Chu, MD1
  1. 1Stanford University School of Medicine, Division of Endocrinology, Stanford, California
  2. 2Santa Clara Valley Medical Center, San Jose, California
  1. Address correspondence and reprint requests to James W. Chu, MD, Diabetes Care Center, 1260 S. Main St., Suite 201, Salinas, CA 93901. E-mail: jchu{at}diabetescarecenter.com
Diabetes Care 2005 Sep; 28(9): 2238-2239. https://doi.org/10.2337/diacare.28.9.2238
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading
  • ADA, American Diabetes Association
  • SLE, systemic lupus erythematosus
  • SMBG, self-monitored blood glucose
  • SSZ, sulfasalazine

Salicylates are therapeutic agents clinically useful in treating inflammatory bowel diseases and arthropathies. These drugs have also demonstrated glucose-lowering effects in type 2 diabetes (1–2). Sulfasalazine (SSZ) is a compound that is cleaved in vivo to 5-aminosalicylic acid (a salicylate) and sulfapyridine (a sulfonamide antibiotic). We report a case of a patient with systemic lupus erythematosus (SLE) and type 2 diabetes on high-dose insulin therapy, who after initiating SSZ experienced recurrent severe hypoglycemia and eventually achieved normoglycemia without the need for diabetes medications. After caring for the index patient, and then two others manifesting similar metabolic responses to SSZ, we conducted a systematic chart review to evaluate glycemic effects of SSZ in a cohort of diabetic patients.

HISTORY AND EXAMINATION

A 37-year-old woman with SLE, iron-deficiency anemia, metamphetamine usage, and a 1-year history of type 2 diabetes was referred to the Santa Clara Valley Medical Center (SCVMC) diabetes clinic for treatment of severe hyperglycemia. She took 100 units of insulin daily (NPH 35 units b.i.d., regular 10 units t.i.d.), yet her self-monitored blood glucose (SMBG) values consistently exceeded 16.7 mmol/l, and she experienced polyuria/dipsia and blurry vision. Other medications were prednisone 7.5 mg/day and hydroxychloroquine. On examination, the patient was cachexic, weighing 44 kg. Laboratory evaluation revealed normal thyroid, hepatic, and renal function, with no microalbuminuria. The HbA1c (A1C) value was 12.3%. During the next 2 months, insulin doses were gradually increased to 170 units/day, but SMBG values persisted at 13.9–22.2 mmol/l.

The patient subsequently started SSZ (500 mg b.i.d.) for SLE treatment. One month later she was found unresponsive with a blood glucose level of 1.8 mmol/l. Despite decreasing insulin doses to 50 units/day over the next 2 weeks, the patient reported persistent hypoglycemia, with SMBG values <3.9 mmol/l. Insulin was discontinued and glyburide 10 mg b.i.d. was started. Two months later, the patient suffered another severe hypoglycemic episode requiring medical assistance. She then stopped all diabetes medications. Despite a weight gain of >22 kg, the patient’s follow-up A1C was 5.0%, and her SMBG ranged from 4.4 to 6.1 mmol/l. Her physical activity levels and other medications remained unchanged during this course.

INVESTIGATION

We investigated whether SSZ therapy had glucose-lowering effects in other diabetic patients. Through the SCVMC pharmacy database of 171,690 outpatients, we identified 37 patients from 2001 to 2004 who concomitantly activated prescriptions for SSZ and either insulin, acarbose, sulfonylurea, metformin, or thiazolidinedione. Excluded from analysis were eight patients who took SSZ for <3 months and 11 others with insufficient data for analysis. In the remaining patients with >3 months of SSZ exposure, we performed a chart review to determine A1C values when not taking SSZ (designated either 3–6 months before SSZ initiation or 3–6 months after SSZ discontinuation) in comparison with A1C values when taking SSZ (most recent A1C if continuously taking SSZ or the A1C 0–3 months before SSZ discontinuation).

The 18 analyzable patients all had type 2 diabetes and were prescribed SSZ with a mean dose of 2,278 mg/day (range 500-4,000) for a mean duration of 1.7 years (0.3–3.4) to treat various underlying inflammatory conditions, including psoriatic arthropathy (7), rheumatoid arthritis (7), inflammatory bowel diseases (2), and SLE (2). The difference in average A1C in situations when taking (6.4%) and not taking (8.2%) SSZ was −1.8% (−8.9 to 2.1, P = 0.02 by paired t test). Of the studied patients, 41% attained an American Diabetes Association (ADA)-defined A1C goal ≤7.0% when not taking SSZ, while 78% reached this goal while taking SSZ (P < 0.03 by χ2 test). Regarding diabetes medication dose changes while taking SSZ, four patients stopped all diabetes medications, four lowered doses, four increased doses, and six did not change doses.

Of 18, 13 were considered “responders,” manifesting improved A1C (ΔA1C >0.5%) while taking SSZ. The five remaining patients were “nonresponders,” with three having no change (ΔA1C <0.5%) and two experiencing increased A1C on SSZ therapy. In comparing the two response groups, there was no difference in age, sex, or SSZ duration (P > 0.20), but daily SSZ dose (2,540 vs. 1,600 mg, P = 0.11) trended higher, and baseline A1C (9.1 vs. 6.4%, P < 0.02) was significantly higher among the responders. When considering only the subgroup of 13 responders, the difference in average A1C in situations when taking (6.3%) and not taking (9.1%) SSZ was −2.7% (range −0.9 to −8.9, P < 0.01 by paired t test), with 11 reaching the ADA A1C goal ≤7.0%, 7 achieving normoglycemia (A1C ≤6.0%), 5 discontinuing or lowering diabetes medication doses, and 3 experiencing repeated severe hypoglycemia (SMBG <3.3 mmol/l).

CONCLUSIONS

Although the hypoglycemic potential of salicylate therapy was demonstrated >100 years ago (1) and again recently (2), clinical utility in diabetes treatment has been limited by nausea, vomiting, tinnitus, and deafness associated with high-dose therapy (3–5). Although the mechanisms by which salicylates affect glucose metabolism are not completely elucidated, studies have described both inhibitory effects on hepatic glucose production (6,7) and improved insulin action from inhibition of the kinases IKK-B (inhibitor of κB) and IKK-A (inhibitor of κA) involved in tissue inflammation (8–10). Furthermore, with sulfasalazine, which is cleaved to both a salicylate and a sulfonamide antibiotic, it is possible that the sulfonamide component contributes further to glucose-lowering effects (11,12).

Our case report and retrospective case series illustrate several important points concerning the hypoglycemic effects of SSZ. First, the compelling glucose-lowering effects of SSZ occur at standard prescribed doses as low as 1 g/day. Second, because its glucose-lowering effect has not been previously detailed, SSZ induced unexpected dangerous hypoglycemia in ∼17% of our cohort. Third, because the average A1C value decrease for the entire cohort of patients was 1.8%, with a greater percentage achieving an ADA goal A1C while taking SSZ, one can speculate about the general efficacy of SSZ therapy in treating type 2 diabetes. In summary, our results suggest that glycemic control in diabetic patients should be very closely monitored when newly starting SSZ. Furthermore, in view of the dramatic findings in our small retrospective series, further studies examining the metabolic effects of SSZ are warranted.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted June 14, 2005.
    • Received May 4, 2005.
  • DIABETES CARE

References

  1. ↵
    Williamson RT, Lond MD: On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1: 760–762, 1901
    OpenUrlFREE Full Text
  2. ↵
    Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109: 1321–1326, 2002
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Gross M, Greenberg LA: The Salycilates. New Haven, CT, Hillhouse Press, 1948
  4. Reid J, MacDougall AI, Andrews MM: Aspirin and diabetes mellitus. Br Med J 2: 1071–1074, 1957
  5. ↵
    Gilgore SG: The influence of salicylate on hyperglycemia. Diabetes 9: 392–393, 1960
    OpenUrlFREE Full Text
  6. ↵
    Woods HF, Stubbs WA, Johnson G, Alberti KG: Inhibition by salicylate of gluconeogenesis in the isolated perfused rat liver. Clin Exp Pharmacol Physiol 1: 535–540, 1974
    OpenUrlCrossRefPubMed
  7. ↵
    Miller JD, Ganguli S, Artal R, Sperling MA: Indomethacin and salicylate decrease epinephrine-induced glycogenolysis. Metabolism 34: 148–153, 1985
    OpenUrlCrossRefPubMed
  8. ↵
    Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77–80, 1998
    OpenUrlCrossRefPubMedWeb of Science
  9. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293: 1673–1677, 2001
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108: 437–446, 2001
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Johnson JA, Kappel JE, Sharif MN: Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient. Ann Pharmacother 27: 304–306, 1993
    OpenUrlPubMedWeb of Science
  12. ↵
    Lee AJ, Maddix DS: Trimethoprim/sulfamethoxazole-induced hypoglycemia in a patient with acute renal failure. Ann Pharmacother 31: 727–732, 1997
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Diabetes Care: 28 (9)

In this Issue

September 2005, 28(9)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Glucose-Lowering Effects of Sulfasalazine in Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
Citation Tools
Glucose-Lowering Effects of Sulfasalazine in Type 2 Diabetes
Romana M. Haas, Phoebe Li, James W. Chu
Diabetes Care Sep 2005, 28 (9) 2238-2239; DOI: 10.2337/diacare.28.9.2238

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Glucose-Lowering Effects of Sulfasalazine in Type 2 Diabetes
Romana M. Haas, Phoebe Li, James W. Chu
Diabetes Care Sep 2005, 28 (9) 2238-2239; DOI: 10.2337/diacare.28.9.2238
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • HISTORY AND EXAMINATION
    • INVESTIGATION
    • CONCLUSIONS
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Increased Second Trimester Maternal Glucose Levels Are Related to Extremely Large-for-Gestational-Age Infants in Women With Type 1 Diabetes
  • The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients
  • Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor
Show more Clinical Care/Education/Nutrition

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • BMJ Open - Diabetes Research & Care
  • Standards of Medical Care in Diabetes
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2019 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.